Navigation Links
Oncolytics Biotech(R) Inc. Announces Second Quarter 2010 Results
Date:7/29/2010

ed "Two-Stage Phase I Dose-Escalation Study of Intratumoural Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced Cancers," in the online version of the journal Clinical Cancer Research that showed that 100% of 14 evaluable patients were stable disease or better (7 partial responses, and 7 stable disease); - A poster presentation at the American Association for Cancer Research's 101st Annual Meeting in Washington, DC entitled "Reovirus replication in ovarian and peritoneal tumors after intravenous administration," covering correlative results from a Phase 1/2 study with reovirus in patients with ovarian, primary peritoneal and fallopian tube carcinoma, sponsored by the National Cancer Institute under its Clinical Trials Agreement with Oncolytics;

Clinical Program

        -  Opening of enrollment in the Phase 3 trial examining REOLYSIN in
           combination with paclitaxel and carboplatin in patients with
           platinum-refractory head and neck cancers;
        -  Receipt of a No Objection Letter from Health Canada to conduct its
           Phase 3 trial examining REOLYSIN in combination with paclitaxel
           and carboplatin in patients with platinum-refractory head and neck
           cancers;
        -  Receipt of approval from the Belgian Federal Agency for Medicines
           and Health Products (FAMHP) to conduct its Phase 3 trial examining
           REOLYSIN in combination with paclitaxel and carboplatin in
           patients with platinum-refractory head and neck cancers;
        -  Start of enrollment in a U.S. Phase 2 clinical trial using
           intravenous administration of REOLYSIN in combination with
           gemcitabine (Gemzar(R)) in patients with advanced pancreatic
           cancer at the Cancer Therapy & Research C
'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Oncolytics Biotech(R) Inc. Announces Issuance of 35th U.S. Patent
2. Oncolytics Biotech(R) Inc. To Host Conference Call to Discuss Updated U.K. Phase I/II Trial Head and Neck Cancer Data Being Presented at the ASCO Annual Meeting
3. Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
4. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Pancreatic Cancer Clinical Trial
5. Oncolytics Biotech(R) Inc. Announces Opening of Enrollment in Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
6. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at ASCO Annual Meeting
7. Oncolytics Biotech(R) Inc. Announces Phase I Colorectal Cancer Study
8. Oncolytics Biotech(R) Inc. Announces Publication of Phase I Clinical Trial Results in Clinical Cancer Research
9. Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results
10. Oncolytics Biotech(R) Inc. Announces Details of 2010 Annual Shareholder Meeting
11. Oncolytics Biotech(R) Inc. Completes Patient Enrollment in Phase I Portion of U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014 /PRNewswire/ - RepliCel Life Sciences ... medicine company focused on the development of autologous cell ... of the University of Calgary in conjunction with co-authors ... which further validates the company,s ongoing clinical research using ... of pattern baldness. The paper entitled " ...
(Date:12/22/2014)... DIEGO , Dec. 22, 2014 GenomeDx ... the Decipher Prostate Cancer Classifier, a genomic test for ... in node-negative, high-risk men managed by radical prostatectomy without ... radical prostatectomy is relatively uncommon, using tumor genomics to ... of metastatic disease is an important advance. The study ...
(Date:12/22/2014)... The American Journal of ... research, reviews and editorials addressing developments and pathways ... published a provocative article exploring the role of ... potential treatment of prostate cancer. , The ... the possibility that there could be a connection ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
Breaking Biology Technology:Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3
... PharmSource Lead Sheet upgrades database resources to help companies serving ... , ... Springfield, VA (PRWEB) November ... Information Services, Inc. (PharmSource) announces the expansion of its PharmSource ...
... quantum computing is that it will dramatically outshine traditional ... factoring large numbers, creating uncrackable codes and simulating the ... that direction, if you,ll pardon the pun, has been ... a paper published in the journal Nature . ...
... ARBOR, Mich., Nov. 21 MichBio, the association ... service providers to its fourth annual Expo on ... Financial ShowPlace in Novi, MI. The MichBio ... industry professionals.,In addition, this year,s event attracted 56 ...
Cached Biology Technology:PharmSource Introduces Proprietary Resource for Identifying New Business Opportunities in Bio/Pharma 2Stanford: Quantum computing spins closer 2MichBio Expo Draws Nearly 500 Professionals; Career Day Raises Profile 2MichBio Expo Draws Nearly 500 Professionals; Career Day Raises Profile 3
(Date:12/17/2014)... 15, 2014 Research and Markets ... the "Samsung Galaxy S5 - Home Button ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... sensing technology than the iPhone 5S, Samsung introduces ... its product. The Galaxy S5 home ...
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM ... Practices (GCP) audit to confirm its adherence to ... This accomplishment enables HITLAB to conduct regulated smart ... highest principles for patient safety and research quality. ... healthcare access, quality, and delivery with innovative technology," ...
(Date:12/17/2014)... , Dec. 16, 2014 Research and ... the addition of the "Global Chemical Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 ... the increasing demand for medical sensors in biomedical ... data for quick and correct diagnosis during surgical ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... dip in the ocean, nuclear fuel is probably the farthest thing ... of just 3 parts per billion, but it adds up. Combined, ... enough to potentially fuel the worlds nuclear power plantsfor 6,500 years., ... source since the 1960s, but previous approaches have been too expensive ...
... have discovered a biological explanation for why low levels ... why breathing treatments help SMA patients live longer. The ... SMA is a progressive neurodegenerative disease that causes muscle ... one of the most common treatment options for severe ...
... scientist Chittaranjan Kole was awarded the Outstanding Crop Scientist ... was one of three scientists to receive the award ... field of crop science. He also chaired a special ... month, "Genomics and Breeding of Climate Resilient Crops ...
Cached Biology News:Low oxygen levels may decrease life-saving protein in spinal muscular atrophy 2
... The TNT Coupled Reticulocyte Lysate Systems(a,b,c,d) ... in vitro translations: a single-tube, coupled ... greatly simplify the process and reduce ... vitro translation results. Standard rabbit reticulocyte ...
... Identical to the DH-2000, except that it ... 190-1700 nm wavelength range and comes with a ... up to 5 Hz) The DH-2000 ... spectrum of deuterium and tungsten halogen light sources ...
... cuff pump is a dedicated cuff pump for ... pump replaces manual inflation and can be used ... for mouse and rat; from single up to ... cuff pump has adjustable cut-off pressure in 50 ...
... sera are specifically depleted of a single ... depleted protein, the alternative and classical pathways ... ideal for the detection and quantitation of ... been used to assess complement activation in ...
Biology Products: